Xiangkun Yang, Ph.D.Senior Scientist II at Prime MedicineSpeaker
Profile
Dr. Xiangkun (Shawn) Yang has 7 years of experience in the analytical and bioanalytical development area of biopharmaceutical industry. Dr. Yang obtained his Ph.D. from College of Pharmacy, University of Georgia in 2017. After that, Dr. Yang worked as an ORISE fellow at FDA, and at Regeneron Pharmaceuticals to develop novel analytical methods to characterize and quantitate antibody-based therapeutics and protein biomarkers. Dr. Yang joined Prime Medicine’s CMC organization (Technical Development & Operations, TDO) in 2021. Since then, Dr. Yang has been leading Prime’s guide RNA analytics team to support all aspects of analytical development including new method development, qualification, stability, tech transfer and regulatory submission for gene editing critical materials, drug substances and drug products.
Agenda Sessions
Analytical Development for Prime Editing Guide (peg)RNAs
, 11:45amView Session